FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer
- 6 March 2026
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (10) , 1923-1927
Abstract
On May 5, 2021, and March 19, 2025, the Food and Drug Administration (FDA) granted accelerated and regular approval, respectively, for pembrolizumab plus trastuzumab and platinum-based chemotherapy for unresectable or metastatic human epidermal growth factor receptor 2 (HER2) gastric or gastroesophageal junction carcinoma. Both approvals were based on KEYNOTE-811, a randomized, multiregional trial comparing pembrolizumab plus trastuzumab and chemotherapy versus placebo plus trastuzumab and chemotherapy. Accelerated approval (AA) was granted based on the overall response rate (ORR) in the first 264 patients randomized, showing a statistically significant improvement with pembrolizumab (74.4% vs. 51.9%, P = 0.00006). The final overall survival (OS) analysis demonstrated a clinically meaningful improvement, with a median OS of 20.0 months [95% confidence interval (CI), 17.8–22.1] and 16.8 months (95% CI, 14.9–18.7) in the pembrolizumab and placebo arms, respectively [hazard ratio (HR), 0.80 (95% CI, 0.67–0.94); P = 0.004]. However, in exploratory subgroup analyses, treatment benefit seemed to be driven by the programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥1 population [85% of patients, with an OS HR of 0.79 (95% CI, 0.66–0.95)], whereas in the PD-L1 CPS <1 subgroup (15% of patients) treatment with pembrolizumab did not show improvement [HR, 1.10 (95% CI, 0.72–1.68)]. These results are consistent with analysis of pembrolizumab and other immune checkpoint inhibitors across multiple clinical trials in patients with gastric cancer. KEYNOTE-811 utilized a “one-trial” approach allowing AA based on the response rate with subsequent conversion to regular approval based on survival outcomes. KEYNOTE-811 also provided data for earlier access to therapies in a first-line metastatic setting, following FDA’s Project FrontRunner approach.Keywords
Funding Information
- U.S. Food and Drug Administration
This publication has 10 references indexed in Scilit:
- Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trialThe Lancet, 2023
- Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal CancerJAMA Oncology, 2022
- The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerNature, 2021
- Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case ExamplesClinical Cancer Research, 2021
- “Dangling” Accelerated Approvals in OncologyNew England Journal of Medicine, 2021
- HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ StudyJournal of Clinical Oncology, 2021
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic targetAnnals of Oncology, 2008
- Assessment of a HER2 scoring system for gastric cancer: results from a validation studyHistopathology, 2008